Evidence map›Paper›PMID 39741294›Full record

ArticleRespiratory research2024

Identification of progressive pulmonary fibrosis: consensus findings from a modified Delphi study.

Athol U Wells, Simon L F Walsh, Ayodeji Adegunsoye, Vincent Cottin, Sonye K Danoff, Anand Devaraj, Kevin R Flaherty, Peter M George, Kerri A Johannson, Martin Kolb and 5 more

Abstract readConsensus Statement
In one paragraph

Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. A multidimensional index with SpORespiratory research & clinical practice · 2026
    Article
  4. Progressive pulmonary fibrosis: the importance of identification and intervention.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Athol U WellsRoyal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK. RBHILD@rbht.nhs.uk.
Simon L F WalshNational Heart and Lung Institute, Imperial College London, London, UK.
Ayodeji AdegunsoyeUniversity of Chicago, Chicago, USA.
Vincent CottinNational Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France.
Sonye K DanoffJohns Hopkins Medicine, Baltimore, USA.
Anand DevarajRoyal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK.
Kevin R FlahertyUniversity of Michigan, Ann Arbor, USA.
Peter M GeorgeRoyal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK.
Kerri A JohannsonUniversity of Calgary, Calgary, Canada.
Martin KolbMcMaster University and St. Joseph's Healthcare, Hamilton, Canada.
Yasuhiro KondohTosei General Hospital, Aichi, Japan.
Andrew G NicholsonRoyal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK.
Sara TomassettiFlorence University, Florence, Italy.
Elizabeth R VolkmannUniversity of California, David Geffen School of Medicine, Los Angeles, USA.
Kevin K BrownNational Jewish Health, Denver, USA.

Funding

Improving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810k
NHLBI NIH HHS K23 HL146942
6 · The paper itself

Abstract

backgroundWe sought consensus among practising respiratory physicians on the prediction, identification and monitoring of progression in patients with fibrosing interstitial lung disease (ILD) using a modified Delphi process.

methodsFollowing a literature review, statements on the prediction, identification and monitoring of progression of ILD were developed by a panel of physicians with specialist expertise. Practising respiratory physicians were sent a survey asking them to indicate their level of agreement with these statements on a binary scale or 7-point Likert scale (- 3 to 3), or to select answers from a list. Consensus was considered to be achieved if ≥ 70% of respondents selected the same answer, or, for responses on a Likert scale, the median score was ≤ -2 (disagree/not important) or ≥ 2 (agree/important) with an interquartile range ≤ 1. There were three rounds of the survey.

resultsSurveys 1, 2 and 3 were completed by 207, 131 and 94 physicians, respectively, between March 2022 and July 2023. Decline in forced vital capacity (FVC), decline in diffusing capacity of the lungs for carbon monoxide, and increased fibrosis on high-resolution computed tomography (HRCT) were ranked as the most important endpoints for determining progression. Consensus was reached that progression on HRCT or a decline in FVC ≥ 10% from baseline is sufficient to determine progression, and that small declines in multiple endpoints indicates progression. Consensus was reached that a histological pattern of usual interstitial pneumonia (UIP) is a risk factor for progression of ILD, but that a biopsy to look for a UIP pattern should not be performed solely for prognostic reasons. Consensus was not reached on the time period over which progression should be defined. There was consensus that appropriate management of ILD depends on the type of ILD, and that 'despite adequate management' or 'despite usual management' should be included in the definition of progression.

conclusionsThis modified Delphi process provided consensus statements on the identification of ILD progression that were supported by a broad group of clinicians and may help to inform clinical practice until robust evidence-based guidelines are available.

Indexed as

Delphi TechniqueDisease ProgressionPulmonary FibrosisFemaleHumansMaleSurveys and QuestionnairesDisease progressionFibrosis, pulmonaryInterstitial lung diseaseMonitoring, physiologicPulmonary function tests

Identifiers

PMID39741294
PMCPMC11687192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.